Neuromuscular Complications of Covid 19: A Review of Literature

Vijaya Lakshmi Valaparla *

Department of Neurology, University of Texas Medical Branch, Galveston, Texas, USA.

Shireen Mary Jacob

Department of Neurology, University of Texas Medical Branch, Galveston, Texas, USA.

Arpitha Komaragiri

Department of Neurology, Louisiana State University Health, Shreveport, Louisiana, USA.

Anand Vilaschandra Patel

Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.

Chilvana Patel

Department of Neurology, University of Texas Medical Branch, Galveston, Texas, USA.

*Author to whom correspondence should be addressed.


Abstract

Background: There is growing evidence that Covid 19 is associated with a myriad of neurological complications. There is still a paucity of understanding of the various biological underpinnings directing this association.

Results: This was a review of the literature on various neuromuscular complications associated with Covid 19 infection and vaccination. The literature extensively discusses conditions such as Guillain Barre Syndrome (GBS) and Myasthenia Gravis (MG), and the role of Covid 19 in various aspects of the disease process associated with these conditions. Cranial neuropathies have been reported in case studies and series.

Conclusion: Further studies are needed to deepen the understanding of this association and monitor the long-term implications of Covid 19 infection as well as vaccination on the neuromuscular system. This understanding can potentially translate into the determination of effective preventive and treatment strategies for various neuromuscular complications associated with Covid 19.

Keywords: Neuromuscular complications, Covid 19, Covid 19 vaccination, guillain barre syndrome, myasthenia gravis


How to Cite

Valaparla , V. L., Jacob , S. M., Komaragiri , A., Patel , A. V., & Patel , C. (2023). Neuromuscular Complications of Covid 19: A Review of Literature. Asian Journal of Research and Reports in Neurology, 6(1), 170–180. Retrieved from https://journalajorrin.com/index.php/AJORRIN/article/view/93

Downloads

Download data is not yet available.

References

Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367:1260-1263. Available:10.1126/science.abb2507

Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci. 2020;11:995-998. Available:10.1021/acschemneuro.0c00122

Swanson PA II, McGavern DB. Viral diseases of the central nervous system. Curr. Opin. Virol. 2015;11:44-54. Available:10.1016/j.coviro.2014.12.009

Al-Ramadan A, Rabab'h O, Shah J, Gharaibeh A. acute and post-acute neurological complications of COVID-19. Neurol Int. 2021;102:119. Available:10.3390/neurolint13010010

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID19). a multicenter. European study. Eur Arch Otorhinolaryngol. 2020; 277:2251-2261.

Available:10.1007/s00405-020-05965-1

Gogia B, Pujara D, Thottempudi N, Ghanayem T, Ajam Y, Singh A, et al. Impact of Acute Confusional State in Patients With COVID-19 and a Predictive Score. Cureus. 2021; 28:18360. Available:10.7759/cureus.18360

Leemans W, Antonis S, De Vooght W, Lemmens R, Van Damme P. Neuromuscular complications after COVID-19 vaccination: a series of eight patients. Acta Neurol Belg. 2022; 122(3):753-761. DOI: 10.1007/s13760-022-01941-0

Caress JB, Castoro RJ, Simmons Z, Scelsa SN, Lewis RA, Ahlawat A, et al. COVID-19- associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve. 2020; 62:485-491. Available:10.1002/mus.27024

Mahmoud H, Alhathla A, El-Fiky A, Alghamdi MS, Alwafi R, El-Sayed MS, et al. Incidence of Guillain-Barré Syndrome post COVID- 19: a systematic review of case reports and case series. European Review for Medical & Pharmacological Sciences. 2023; 27. Available:10.26355/eurrev_202303_31588

Aladawi M, Elfil M, Abu-Esheh B, Jazar DA, Armouti A, Bayoumi A, et al. Guillain Barre Syndrome as a Complication of COVID- 19: A Systematic Review. Can J Neurol Sci. 2022; 49:38-48. Available:10.1017/cjn.2021.102

Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurol Sci. 2020;41:3039-3056. Available:10.1007/s10072-020-04708-8

Colaizzo E, Puopolo M, Tiple D, Vaianella L, Vanacore N, Milanese A, et al. Guillain-Barré syndrome in patients dying with COVID-19 in Italy: a retrospective study: Guillain-Barré syndrome in 4 COVID-19 deads. Annali dell'Istituto Superiore di Sanità. 2023;59(3):194-8. DOI: 10.4415/ANN_23_03_04

Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, et al. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain. 2021;144:3392-3404. Available:10.1093/brain/awab279

Goudarzi S, Esmaeeli S, Valencia JD, Lu ME, Hales RR, Fehnel CR, et al. Treatment Options for COVID-19-Related Guillain-Barré Syndrome: A Systematic Review of Literature. Neurologist. 2021;7:196-224. Available:10.1097/NRL.0000000000000342

Abara WE, Gee J, Marquez P, Woo J, Myers TR, DeSantis A, et al. Reports of guillain-barré syndrome after COVID-19 vaccination in the United States. JAMA Netw Open. 2023;6(2):e2253845. DOI: 10.1001/jamanetworkopen.2022.53845

Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain-Barré Syndrome following ChAdOx1-S/nCoV-19 Vaccine. Ann Neurol, 2021;90:312 314. Available:https://doi.org/10.1002/ana.26143

Leemans W, Antonis S, De Vooght W, Lemmens R, Van Damme P. Neuromuscular complications after COVID-19 vaccination: A series of eight patients. Acta Neurol Belg. 2022;122(3): 753-761. DOI:10.1007/s13760-022-01941-0

Ogunjimi OB, Tsalamandris G, Paladini A, Varrassi G, Zis P. Guillain-barré syndrome induced by vaccination against COVID-19: A systematic review and meta-analysis. Cureus. 2023; 15(4) 37578. DOI:10.7759/cureus.37578

Tamaki A, Cabrera CI, Li S, Rabbani C, Thuener JE, Rezaee RP, et al. incidence of bell palsy in patients with COVID-19. JAMA Otolaryngol Head Neck Surg. 2021; 147:775. Available:10.1001/jamaoto.2021.1266

Gupta S, Jawanda MK. Surge of Bell's Palsy in the era of COVID- 19: Systematic review. Eur J Neurol. 2022; 29:2543. Available:10.1111/ene.15371

Ali W, Ahmad T, Ahmad K, Chattaraj A, Pillai A. BELL PALSY: IT CAN BE COVID-19!. Critical Care Medicine. 2022;50:143.

Gogia B, Gil Guevara A, Rai PK, Fang X. A case of COVID-19 with multiple cranial neuropathies. Int J Neurosci. 2020;30:1-3. Available:10.1080/00207454.2020.1869001

Namavarian A, Eid A, Ziai H, Cheng EY, Enepekides D. Facial nerve paralysis and COVID-19: A systematic review. Laryngoscope. 2023;133(5):1007-1013. DOI: 10.1002/lary.30333

Gupta S, Jawanda MK, Taneja N, Taneja T. A systematic review of Bell's Palsy as the only major neurological manifestation in COVID-19 patients. J Clin Neurosci. 2021;90:284-292. Available:10.1016/j.jocn.2021.06.016

Khurshid A, Khurshid M, Sohail A, Raza IM, Ahsan MK, Alam Shah MF. Facial palsy as a manifestation of COVID-19: A systematic review of cases. Health Sci Rep. 2022; 5:887. Available:10.1002/hsr2.887

Albakri K, Khaity A, Atwan H, Saleh O, Al-Hajali M, Cadri S, et al. Bell's Palsy and COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2023;11(2):236. DOI:10.3390/vaccines11020236

Shahsavarinia K, Mahmoodpoor A, Sadeghi-Ghyassi F, Nedayi A, Razzaghi A, Saadat AZ, et al. Bell's Palsy and COVID-19 vaccination: A systematic review. Med J Islam Repub Iran. 2022;36:85. Published 2022 Jul 30. DOI: 10.47176/mjiri.36.85

Khurshid M, Ansari I, Ahmad H, Ghaffar H, Khurshid A, Shahid A, et al. Development of facial palsy following COVID-19 vaccination: A systematic review. Ann Med Surg (Lond). 2022;82:104758. DOI: 10.1016/j.amsu.2022.104758

Kim S, Kang M, Park JS, Seok HY. Risk and characteristics of Bell's palsy in adults as an adverse event following COVID-19 vaccination: A retrospective study. Acta Neurol Belg. 2023;1-9. DOI: 10.1007/s13760-023-02204-2

Soeiro T, Salvo F, Pariente A, Grandvuillemin A, Jonville-Béra AP, Micallef J. Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy. Therapie. 2021;76(4):365-367.

DOI: 10.1016/j.therap.2021.03.005

Siepmann T, Kitzler HH, Lueck C, Platzek I, Reichmann H, Barlinn K. Neuralgic amyotrophy following infection with SARS-CoV-2. Muscle Nerve. 2020;62: 68-70. Available:10.1002/mus.27035

Mitry MA, Collins LK, Kazam JJ, Kaicker S, Kovanlikaya A. Parsonage-turner syndrome associated with SARS-CoV2 (COVID-19) infection. Clin Imaging. 2021;72:8- Available:10. 10.1016/j.clinimag.2020.11.017

Cacciavillani M, Salvalaggio A, Briani C. Pure sensory neuralgic amyotrophy in COVID-19 infection. Muscle Nerve. 2021;63:7-8. Available:10.1002/mus.27083

Ismail II, Abdelnabi EA, Al-Hashel JY, Alroughani R, Ahmed SF. Neuralgic amyotrophy associated with COVID-19 infection: a case report and review of the literature. Neurol Sci. 2021; 42:2161-5.

Available:10.1007/s10072-021-05197-z

Han CY, Tarr AM, Gewirtz AN, Kaunzer UW, Roy-Burman P, Cutler TS, et al. Brachial plexopathy as a complication of COVID-19. BMJ Case Rep. 2021;25:237459. Available:10.1136/bcr-2020-237459

Gee Jin Ng, Yi Rong Chiew, Yongyao Kong, Jasmine Shimin Koh. Neuralgic amyotrophy in COVID-19 infection and after vaccination. Ann Acad Med Singap. 2022;51(6)

Finsterer J, Scorza FA, Scorza C, Fiorini A. COVID-19 associated cranial nerve neuropathy: A systematic review. Bosn J Basic Med Sci. 2022;1:39-45. Available:10.17305/bjbms.2021.6341

Bohania N, Ish P, Nune A, Iyengar KP. Cranial neuropathy in COVID- 19: A case series and review of literature. Infez Med. 2021; 29:609-613. Available:10.53854/liim-2904-15

Wei H, Yin H, Huang M, Guo Z. The 2019 novel coronavirus pneumonia with onset of oculomotor nerve palsy: a case study. J Neurol. 2020;267:1550-3. Available:10.1007/s00415-020-09773-9

Patel HY, Savvides G, Liu Y, Apperson A. Multiple Cranial Neuropathies After COVID-19 Vaccination. Neurology . 2022; 98 (18).

Bara GA, de Ridder D, Maciaczyk J. Can neuromodulation support the fight against the COVID19 pandemic? Transcutaneous non-invasive vagal nerve stimulation as a potential targeted treatment of fulminant acute respiratory distress syndrome. Med Hypotheses. 2020; 143:110093. Available:10.1016/j.mehy.2020.110093

Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schroder AS, Elder C, et al. Neuropathology of patients with COVID-19 in Germany:A post-mortem case series. Lancet Neurol. 2020;19:919-29. Available:10.1016/S1474-4422(20)30308-2

Bulfamante G, Chiumello D, Canevini MP, Priori A, Mazzanti M, Centanni S, et al. First ultrastructural autoptic findings of SARS Cov-2 in olfactory pathways and brainstem. Minerva Anestesiol. 2020; 86:678-9. Available:10.23736/S0375-9393.20.14772-2

Baig AM. Covert pathways to the cranial cavity: Could these be potential routes of SARSCoV-2 to the brain?. ACS Chem Neurosci. 2020;11:3185-7. Available:10.1021/acschemneuro.0c00604

Tugasworo D, Kurnianto A, Retnaningsih, Andhitara Y, Ardhini R, Budiman J. The relationship between myasthenia gravis and COVID- 19: a systematic review. Egypt J Neurol Psychiatr Neurosurg. 2022;58:83. Available:10.1186/s41983-022-00516-3

Stojanov A, Stojanov J, Milosevic V, Malobabic M, Stanojevic G, Stevic M, et al. The impact of the Coronavirus Disease-2019 pandemic on the psychological status and quality of life of myasthenia gravis patients. Ann Indian Acad Neurol. 2020; 23(4):510-514. Available:10.4103/aian.AIAN_551_20

Solé G, Mathis S, Friedman D, Salort- Campana E, Tard C, Bouhour F, Magot A, et al. Impact of coronavirus disease 019 in a French cohort of myasthenia gravis. Neurology. 2021; 96:2109-2120. Available:10.1212/WNL.0000000000011669

Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendoca RH, Souza PVS, et al. Myasthenia gravis and COVID- 19: clinical characteristics and outcomes. Front Neurol. 2020;11:1-5. Available:10.3389/fneur.2020.01053

Jakubíková M, Týblová M, Tesař A, Horakova M, Vlazna D, Rysankova I, et al. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol. 2021;28(10):3418- 3425. Available:10.1111/ene.14951

Businaro P, Vaghi G, Marchioni E, Diamanti L, Arceri S, Bini P, et al. COVID-19 in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve. 2021;64:206-11. Available:10.1002/mus.27324

Rodrigues CL, de Freitas HC, Lima PRO, de Oliveira Junior PH, Fernandes JMA, D’Almeida JAC, et al. Myasthenia gravis exacerbation and myasthenic crisis associated with COVID- 19: case series and literature review. Neurol Sci. 2022; 43(4):2271-2276. Available:10.1007/s10072-021-05823-w

Restivo DA, Centonze D, Alesina A, Marchese-Ragona R. Myasthenia Gravis Associated With Sars-Cov-2 Infection. Ann Intern Med. 2020;173(12):1027-8. Available:10.7326/L20-0845

Rahimian N, Alibeik N, Pishgar E, Dini P, Abolmaali M, Mirzaasgari Z. Manifestation of Ocular myasthenia gravis as an initial symptom of coronavirus disease 2019: A case report. Iran J Med Sci. 2022; 47:385-8. Available:10.30476/IJMS.2021.89841.2061

Sadiq W, Waleed MS, Rizvi TA, Khan S, El Hage H. Myasthenia gravis associated with COVID-19 infection. Cureus. 2023;15(5): 39506. DOI:10.7759/cureus.39506

Gomez F, Mehra A, Ensrud E, Diedrich D, Laudanski K. COVID-19: A modern trigger for Guillain-Barre syndrome, myasthenia gravis, and small fiber neuropathy. Front Neurosci. 2023;17:1198327. DOI:10.3389/fnins.2023.1198327

Chavez A, Pougnier C. A case of COVID-19 vaccine associated new diagnosis myasthenia gravis. J Prim Care Community Health. 2021; 12:21501327211051933. Available:10.1177/21501327211051933

Lee MA, Lee C, Park JH, Lee JH. EARLY-ONSET MYASTHENIA GRAVIS FOLLOWING COVID-19 VACCINATION. J Korean Med Sci. 2022; 37:50. Available:10.3346/jkms.2022.37.e50

Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccine. 2021;9:435. DOI: 10.3390

Lee MA, Lee C, Park JH, Lee JH. Early-onset myasthenia gravis following COVID-19 vaccination. J. Korean Med. Sci. 2022;37:50. DOI: 10.3346/jkms.2022.37.e50

Lee JR, Jaffry M, Mandava K, Rosario S, Jaffry K, Jedidi K, et al. is covid-19 vaccination associated with an increased reporting rate of myasthenia gravis?. A vaccine adverse event reporting system (VAERS) study. Neurology. 2022;98(18)

Arbel A, Bishara H, Barnett-Griness O, Cohen S, Najjar-Debbiny R, Gronich N, et al. Association between COVID-19 vaccination and myasthenia gravis: A population-based, nested case–control study. Eur J Neurol; 2023.

DOI: 10.1111/ene.16025

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China The. Lancet. 2020; 395(10223):497-506. Available:10.1016/S0140-6736(20)30183-5

Saud A, Naveen R, Aggarwal R, Gupta L. covid-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021;11926-021. Available:10.1007/s11926-021-01023-9

Husain R, Corcuera-Solano I, Dayan E, Jacobi AH, Huang M. Rhabdomyolysis as a manifestation of a severe case of COVID- 19: A case report. Radiol Case Rep. 2020;15:1633-1637. Available:10.1016/j.radcr.2020.07.003

Zhang H, Charmchi Z, Seidman RJ, Anziska Y, Velayudhan V, Perk J. COVID-19-associated myositis with severe proximal and bulbar weakness. Muscle Nerve. 2020;62:57-60. Available:10.1002/mus.27003

Gokhale Y, Patankar A, Holla U, Shilke M, Kalekar L, Karnik ND, et al. Dermatomyositis during COVID-19 pandemic (a case series): Is there a cause effect relationship?. J Assoc Physicians India. 2020;68(11):20-24.

Mehan WA, Yoon BC, Lang M, Li MD, Rincon S, Buch K. Paraspinal myositis in patients with COVID-19 infection. Am J Neuroradiol. 2020;41:1949-1952. Available:10.3174/ajnr.A6711

Naveen R, Sundaram TG, Agarwal V, Gupta L. Teleconsultation experience with the idiopathic inflammatory myopathies: A prospective observational cohort study during the COVID-19 pandemic. Rheumatol Int. 2021;41:67-76.

Available:10.1007/s00296-020-04737-8

Camargo Coronel A, Jiménez Balderas FJ, Quiñones Moya H, Hernández Zavala MR, Mandinabeitia Rodríguez P, Hernández Vázquez JR, et al. Dermatomyositis post vaccine against SARS-COV2. BMC Rheumatol. 2022;6(1):20.

DOI: 10.1186/s41927-022-00250-6

Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: A case-based review. Rheumatol Int. 2022;42(12):2267-2276.

DOI: 10.1007/s00296-022-05176-3

De Marco G, Giryes S, Williams K, Alcorn N, Slade M, Fitton J, et al. A Large cluster of new onset autoimmune myositis in the yorkshire region following SARS-CoV-2 vaccination. Vaccines (Basel). 2022; 10(8):1184.

DOI: 10.3390/vaccines10081184

Syrmou V, Liaskos C, Ntavari N, Mitsimponas K, Simopoulou T, Alexiou I, et al. COVID-19 vaccine-associated myositis: A comprehensive review of the literature driven by a case report. Immunol Res. 2023;71(4):537-546.

DOI: 10.1007/s12026-023-09368-2